Reinhard Angelmar is Professor of Marketing at the INSEAD University in France. Other institutions at which he has held appointments where he taught marketing include the Sloan School (MIT),...
Reinhard Angelmar is Professor of Marketing at the INSEAD University in France. Other institutions at which he has held appointments where he taught marketing include the Sloan School (MIT), Stockholm School of Economics, and the University of Paris-Dauphine.
At INSEAD, Professor Angelmar has taught in the MBA program, the PhD program, and in many executive development programs focussing on marketing and innovation. He directed a International Marketing Programme for many years and has designed and directed tailormade programmes on marketing management, models, innovation and channels of distribution for organizations such as Hewlett-Packard, Janssen-Cilag, Johnson & Johnson, Eli Lilly, Leem (Les Entreprises du Médicament), Pfizer, and the World Medical Association. Other companies with which he has been involved include Almirall, Bristol-Myers Squibb, Ipsen, Novartis, and Novo Nordisk.
Professor Angelmar received his undergraduate education in economics and business administration at the Vienna University of Economics and Business Adminstration in Vienna, Austria, and then went to Northwestern University, Evanston, under a Fulbright scholarship, obtaining an MBA and a PhD Degree at the Kellogg School of Management in marketing. His dissertation won the 'Honorable Mention' 1975-1976 from the American Marketing Association Disseration Competition.
Professor Angelmar is the co-author of three books and has written numerous papers published in journals including the Journal of Marketing, Journal of Marketing Research, Journal of Industrial Economics, European Journal of Operational Research, Organization Science, and Journal of Medical Marketing. He has also written many case studies, which are used in business schools around the world, including many studies on the pharmaceutical industry. His current research interests focus on the pharmaceutical industry and the health care sector.